Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer

Clinical Experience With Peregrine's Anti-Cancer Agent Bavituximab Presented at Leading Symposium on Anti-Angiogenic Agents

Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference

Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer

Peregrine Pharmaceuticals Receives 180-DAY Extension From Nasdaq to Regain Compliance With $1.00 Minimum Bid Price Rule

Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer

Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer

Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008

Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program

Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2008